Mr. Steve Saviuk reports

VALEO PHARMA PROVIDES UPDATE ON OPHTHALMOLOGY BUSINESS UNIT

Valeo Pharma Inc. has noted from the news release issued by Novartis on June 30, 2023, that Novartis has agreed to sell Xiidra, a prescription eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease, as well as several other ophthalmology products to Bausch + Lomb Corp. Simbrinza is not part of the products that are being divested by Novartis. The sale is expected to close before the end of the year.

Valeo entered into a seven-year commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. in July, 2022, for the Canadian rights to Xiidra and Simbrinza and its ophthalmology business unit is engaged in commercial and medical activities for both products.

About Valeo Pharma Inc.

Valeo Pharma is a fast-growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Headquartered in Kirkland, Que., Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

We seek Safe Harbor.